Cancer.Net Associate Editor: Head and Neck Cancers
University of Chicago Medical Center
Everett E. Vokes, MD, is the John Ultmann Professor, Chair of the Department of Medicine and Physician in Chief at the University of Chicago Medical Center. Dr. Vokes served as chief of the Section of Hematology/Oncology for more than a decade and as Interim Dean for the Division of Biological Sciences and Interim CEO for the University of Chicago Medical Center for one year. His interests include clinical and translational research involving head and neck cancer and lung cancer and the interaction of chemotherapy and radiation therapy.
Dr. Vokes earned his medical degree from the University of Bonn Medical School in Bonn, Germany, and then went on to complete his residency in internal medicine at Ravenswood Hospital Medical Center and at the University of Southern California. He completed a fellowship in hematology/oncology at The University of Chicago in 1986.
Dr. Vokes has received many awards and has led many professional groups in the field of hematology/oncology. In 2008, he was one of two recipients of the new Translational Research Professorship from ASCO and is a recipient of a Francis L. Lederer Foundation grant for research on the malignancies of the upper aerodigestive tract. Dr. Vokes also served as principal investigator of the University of Chicago's National Cancer Institute-funded Phase II network from 1994-2009 and has served as chair of the Cancer and Leukemia Group B Respiratory Committee since 2004. Dr. Vokes is an elected member of the prestigious American Society of Clinical Investigation and American Association of Professors.
Dr. Vokes is widely published with over 450 papers and 80 book chapters. He has served on numerous advisory committees and review panels and has served on the editorial boards of several journals, including the Journal of Clinical Oncology, Annals of Oncology, Clinical Lung Cancer, and Investigational New Drugs.
Disclosure: In the past two years, Dr. Vokes has received honoraria from Poniard Pharmaceuticals, Astra -Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, ImClone Systems, Amgen, Genentech, Sanofi-aventis, EMD Serono, Clovis Oncology, Poniard Pharmaceuticals, Celgene, VeriStrat, Pfizer, Agennix; and received research funding from Bristol-Myers Squibb, Genentech, NCI, and ASCO TRP.
Last Updated: November 07, 2011